盐酸右美托咪定(Dexmedetomidine Hydrochloride) - 药物靶点：ADRA2_在研适应症：躁郁症1型，躁郁症2型，精神分裂症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole、(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole、dexmedetomidine

+ [21]

靶点

ADRA2

作用机制

ADRA2激动剂(肾上腺素能受体α-2家族激动剂)

治疗领域

其他疾病神经系统疾病

在研适应症

躁郁症1型躁郁症2型精神分裂症+ [11]

非在研适应症

急性缺血性卒中麻醉脑损伤+ [7]

原研机构

Orion Oyj

在研机构

华益泰康药业股份有限公司

BioXcel Therapeutics, Inc.

Pfizer Australia Pty Ltd.

+ [13]

非在研机构

四川百利药业有限责任公司

Maruishi Pharmaceutical Co., Ltd.

最高研发阶段批准上市

首次获批日期

美国 (1999-12-17),

镇静

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C13H17ClN2

InChIKeyVPNGEIHDPSLNMU-MERQFXBCSA-N

CAS号145108-58-3

关联

4,330

项与盐酸右美托咪定相关的临床试验

CTRI/2024/10/075414

/ Not yet recruiting临床4期

Efficacy of external oblique intercostal block (EOIB) with or without dexmedetomidine on postoperative anaglesia in laparoscopic upper abdominal surgeries – a double blinded randomised control trial - Nil

开始日期2027-09-01

申办/合作机构

All India Institute of Medical Sciences

NCT06685965

/ Not yet recruiting临床2期

Double-Blind, Randomized, Placebo-Controlled, Crossover, Laboratory Based Study With Rollover Extension to Evaluate Safety of Short-term Use of RE03 in Home Setting in Post-Traumatic Stress Disorder (PTSD) Patients With Sleep Disturbances

Post-traumatic stress disorder (PTSD) affects many people who have experienced traumatic events. A common issue with PTSD is severe sleep disturbances, such as nightmares. Current treatments often do not provide sufficient relief, especially for sleep problems. This study aims to determine whether dexmedetomidine - a medication already used in intensive care - can improve sleep quality in PTSD patients and be safely administered both in the sleep lab and in the patient's natural environment.

开始日期2025-04-01

申办/合作机构

Reconnect Labs

[+1]

NCT06769737

/ Not yet recruiting临床4期IIT

The Prolonged Effects of Spinal Dexmedetomidine Versus Intravenous Dexmedetomidine on Spinal Anesthesia With Isobaric Bupivacaine: A Comparative Study

This prospective, double-blinded, randomized clinical trial aims to examine the effects of combining isobaric bupivacaine with dexmedetomidine administered intrathecally (IT), compared to the combination of isobaric bupivacaine administered intrathecally and dexmedetomidine administered intravenously (IV), on spinal anesthesia prolongation time in minutes, time of regression from Bromage score 3 to 0.

开始日期2025-03-01

申办/合作机构

King Abdulaziz Medical City

100 项与盐酸右美托咪定相关的临床结果

登录后查看更多信息

100 项与盐酸右美托咪定相关的转化医学

登录后查看更多信息

100 项与盐酸右美托咪定相关的专利（医药）

登录后查看更多信息

11,219

项与盐酸右美托咪定相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Optimal doses of intranasal esketamine plus dexmedetomidine for sedating toddlers during transthoracic echocardiography: a prospective, double-blind, randomized trial

Article

作者: Du, Zhen ; Qu, Shuangquan ; Xiao, Ting ; Zeng, Li ; Wei, Siwei ; Wang, Lei ; Pei, Dongjie

INTRODUCTION:

Esketamine has unique advantages in combination with dexmedetomidine for sedation in young children, owing to its sympathetic activity and mild respiratory depression. However, the optimal dose is yet to be determined. In this study, we compared the different doses of intranasal esketamine combined with dexmedetomidine for sedation during transthoracic echocardiography in toddlers.

PATIENTS AND METHODS:

A total of 121 eligible children aged 13 years, who were scheduled for transthoracic echocardiography were randomized into three groups. They were treated with intranasal dexmedetomidine 1 mcg.kg^-1 + esketamine 0.5 mg.kg^-1 (group S1), dexmedetomidine 1 mcg.kg^-1 + esketamine 1 mg.kg^-1 (group S2), or dexmedetomidine 1 mcg.kg^-1 + esketamine 1.5 mg.kg^-1 (group S3). The primary outcome was the success rate of sedation, other outcomes included HR, SpO₂, onset time, wake-up time, and adverse effects.

RESULTS:

The success rate of sedation was significantly higher in groups S2 (85.4%) and S3 (87.5%) than ingroup S1 (60%) (p = 0.004). The baseline HR and SpO₂ did not differ between the groups at the corresponding time points following drug administration. The onset time and duration of sedation in group S1 were significantly longer than those in groups S2 and S3 (p = 0.000). However, there were no differences in the wake-up time or adverse effects among the three groups.

CONCLUSIONS:

Intranasal administration of 1 mg.kg^-1 esketamine combined with 1 mcg.kg^-1 dexmedetomidine provided satisfactory sedation in young children undergoing transthoracic echocardiography. This sedative approach offers a rapid onset of awakening with few side effects.

CLINICAL TRIAL REGISTRATION NUMBER:

ChiCTR2200060976, 2022/06/14 (trail from August 2022 to January 2023).

2025-04-01·DEN open

Feasibility of non‐anesthesiologist‐administered sedation with dexmedetomidine and midazolam during endoscopic submucosal dissection of upper gastrointestinal tumors

Article

作者: Ishido, Kenji ; Matsuda, Hiromi ; Tanabe, Satoshi ; Kitahara, Gen ; Furue, Yasuaki ; Kusano, Chika ; Watanabe, Akinori ; Wada, Takuya ; Okamoto, Hirotsugu

Abstract:

Objectives:

The efficacy and safety of a sedation regimen combining dexmedetomidine and midazolam during endoscopic submucosal dissection for upper gastrointestinal tumors remains unclear. In this study, we aimed to evaluate the efficacy and safety of this sedation regimen, where non‐anesthesiologists performed sedation.

Methods:

Sixty‐eight patients who underwent endoscopic submucosal dissection for upper gastrointestinal tumors, sedated by non‐anesthesiologists, were retrospectively evaluated. The sedation was performed by non‐anesthesiologists as part of on‐the‐job training (OJT) under anesthesiologists' supervision. Each non‐anesthesiologist received OJT at least thrice. Proficiency levels were assessed during the third OJT session. The target sedation depth was a Richmond Agitation‐Sedation Scale of −2 to −4, with 2 L/min of oxygen delivered via a nasal cannula at sedation initiation. The treatment completion rates, which measured efficacy and safety, were assessed by the frequencies of respiratory depression, hypotension, and bradycardia.

Results:

The study included 14, 52, and two patients with superficial esophageal cancer, early gastric cancer, and gastric adenoma, respectively. The median treatment time was 68 and 84 min for superficial esophageal cancer, early gastric cancer, and adenoma, respectively. Endoscopic submucosal dissection was completed in all patients. No severe sedation‐related adverse events were reported; however, peripheral arterial oxygen saturation <90%, hypotension, and bradycardia occurred in 1 (1.5%), 30 (44.1%), and 30 patients (44.1%), respectively. All 22 non‐anesthesiologists who underwent the proficiency evaluation passed the test.

Conclusions:

A sedation regimen combining dexmedetomidine and midazolam can be feasibly administered by non‐anesthesiologists. Further studies are needed to verify the effectiveness of OJT.

2025-04-01·Neurology-Clinical Practice

A Real-World Prospective Multiple Sclerosis Pregnancy Registry in the United States

Article

作者: Lathi, Ellen ; Sadovnick, Adele Dessa ; Solomon, Andrew J. ; Cabot, Ann ; Severson, Christopher ; Ionete, Carolina ; Stankiewicz, James M. ; Zurawski, Jonathan ; Pol-Patil, Jeta ; Klawiter, Eric C. ; Morales, Idanis Berrios ; Manieri, Maria Claudia ; Katz, Joshua ; Mahlanza, Tatenda Dawn ; Houtchens, Maria K.

Background and Objectives:

Multiple sclerosis (MS) affects more than 1 million people in the United States, including reproductive-age women. There has been a paucity of prospective, pregnancy registries based on MS disease rather than medication exposures. A prospective MS pregnancy registry (PREG-MS) was established in 2017 as a prospective, single-cohort, real-world MS pregnancy registry in New England States of the United States, with goals to evaluate (1) course of MS and disease-modifying therapies (DMT) use during conception attempts and in the peripartum period, (2) pregnancy outcomes in women with MS (WwMS), and (3) longer-term developmental outcomes in offspring of WwMS.

Methods:

Between 2017 and 2020, PREG-MS recruited from 11 preselected academic and community MS centers and followed WwMS and their children from conception attempts and any pregnancy trimester, up to 3 years of postpartum. Comprehensive neurologic, obstetric, and pediatric development information was collected through telephone interviews and medical records.

Results:

One hundred forty-six patients were enrolled between 2017 and 2020; there were 122 pregnancies from 135 participants, and 105 infants were born on study. 24.6% pregnancies were unplanned; 14.1% had an infertility diagnosis. Assisted reproductive technologies were used by 12.6%. 54% of pregnancies were designated as "high-risk", and ∼40% had peripartum obstetrical complications with 17% adverse pregnancy outcomes. Mean baseline Expanded Disability Status Scale was 1.09 ± 0.84. ∼85% were treated with DMTs up to the time of conception. 19.7% had 1 or more relapses within prepregnancy year, correlating with increased duration of conception attempts (p < 0.0001). 12% had intrapartum, and 24.5% had postpartum relapses. Any fertility treatments predicted intrapartum relapses independent of DMT status (OR 5.18, 95% CI 1.58-17.02, p = 0.007). 33.6% were exposed to DMTs in pregnancy. Intrapartum relapses (p = 0.008) and high-risk pregnancy (p = 0.036) were associated with postpartum exacerbations.

Discussion:

Our real-world, prospective, nondisabled MS pregnancy cohort had a sizable proportion of participants with clinical disease activity in the prepartum and intrapartum period, despite high-DMT utilization prepartum. A greater-than-expected number of participants were considered to have high-risk pregnancies and reported peripartum complications. The use of any fertility treatments was independently predictive of intrapartum relapses, supporting hormonal-immune interactions as disease modulators in MS. Larger prospective, longitudinal registries are needed to confirm our findings.

Trial Registration Information:

Clinical trial registration number: NCT03368157.

385

项与盐酸右美托咪定相关的新闻（医药）

2025-01-15

·PRNewswire

Parnell Launches PropofolVet Multidose, First Generic Propofol Injectable Emulsion for Dogs

Versatile New Anesthetic Delivers Consistent Results While Simplifying Practice Operations OVERLAND PARK, Kan., Jan. 15, 2025 /PRNewswire/ -- Parnell, a pet care products manufacturer focused on delivering reliable high-quality products, today announced the launch of PropofolVet Multidose, an anesthetic injection designed specifically for veterinary practices. This new solution offers veterinarians enhanced flexibility and efficiency in their anesthesia protocols while maintaining the highest standards of patient care. Continue Reading PropofolVet Multidose, an anesthetic injection designed specifically for veterinary practices. PropofolVet Multidose provides veterinarians with a versatile anesthetic option for dogs, supporting both induction of anesthesia and maintenance of general anesthesia through intermittent bolus injections for short procedures. The product can also be used for induction when maintenance is provided by inhalant anesthetics. "We understand the complex demands veterinary professionals face in their anesthesia protocols," said Chelsie Estey MSc, DVM, DACVIM (Neurology) and Vice President of U.S. Pet Care, Parnell. "PropofolVet Multidose is an important addition to our sedation and anesthesia portfolio. We're committed to ensuring veterinary teams not only have access to our products but feel confident using them in practice." Key features of PropofolVet Multidose include: Quality and cost-effective alternative to PropoFlo™ 28 First generic propofol injectable emulsion for dogs 28-day in-use shelf life No refrigeration required Delivers consistent, high-quality induction "As the first generic propofol in the veterinary anesthesia and sedation category, PropofolVet Multidose addresses a critical market need by providing veterinarians with a high-quality, cost-effective solution that enhances practice efficiency without compromising care standards," said Pablo Lamberto, DVM and SVP and President of U.S. Operations for Parnell. The launch complements Parnell's comprehensive anesthesia and sedation portfolio, which includes Dexmedetomidine Hydrochloride Injection and CONTRASED™ (atipamezole hydrochloride). This integrated suite of products streamlines inventory management and provides veterinary practices with a reliable, complete solution for their sedation and anesthesia needs. Veterinary professionals can contact their distributor representative or visit to learn more. About Parnell Parnell is a fully integrated, veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. We currently manufacture and market products for companion and production animals in 10 countries and augment our production animal pharmaceutical products with our proprietary software platform mySYNCH™. ©2025 Parnell Technologies Pty LTD. CONTRASED and mySYNCH are trademarks of Parnell Technologies Pty LTD. Other product names are trademarks of their respective owners. MKT-24-057 PC US. SOURCE Parnell WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-01-07

·米内网

第十一批国采12个品种备战！超900亿市场海思科亮了，独家注射剂称王，石四药、华海蓄力

精彩内容日前，第十批国采中选结果正式公布，新一批次国采在路上。神经系统药物是纳入国采品种数TOP4的治疗大类，在系列政策加持下，该大类市场跌宕起伏，格局持续洗牌。目前197个神经系统化药已有企业过评/视同过评，人福领跑过评榜；54个品种（以通用名计）已纳入国采，12个品种备战第十一批国采，石四药、华海等均有多个品种在列。跌宕起伏！超900亿市场人福称王，海思科亮了米内网数据显示，近年来中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端神经系统化药（不含生物药，下同）市场起起落落，但总体维持在900亿元以上的销售规模。近年来中国公立医疗机构终端神经系统化药销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局从治疗亚类看，其它神经系统药物占主导地位，近年来占比均超过20%；麻醉剂、止痛药位居第二、第三，且占比均呈逐年上升趋势；此外，精神兴奋药、精神安定药近年来占比也均在10%以上。 2024H1中国公立医疗机构终端神经系统化药亚类分布情况来源：米内网中国公立医疗机构药品终端竞争格局从用药途径看，注射剂为神经系统化药用药主途径，但近年来占比持续下滑；以片剂、胶囊剂等为代表的内服用药紧接在后，且占比逐年提升，2024上半年超过40%。 2024H1中国公立医疗机构终端神经系统化药用药途径来源：米内网中国公立医疗机构药品终端竞争格局 TOP20集团中，人福医药、石药集团、扬子江药业、恒瑞医药、恩华药业依次位列前五，其中人福医药稳居首位，且市场份额较2023年有所提升；从销售额增幅看，海思科、灵北、晖致、NAPP同比增长均达两位数。 2024H1中国公立医疗机构终端神经系统化药TOP5集团来源：米内网中国公立医疗机构药品终端竞争格局 TOP20洗牌！“一哥”易主，4款国产新药上榜 2024上半年神经系统化药TOP20产品中，地佐辛注射液稳居多年的龙头宝座不保，石药集团独家新药丁苯酞氯化钠注射液成功上位，注射用盐酸瑞芬太尼稳居第三。20个产品中有7个2024上半年销售额达10亿元以上，其中TOP3产品均超20亿元。 2024H1中国公立医疗机构终端神经系统化药TOP20产品来源：米内网综合数据库从销售额增长情况看，8个品种逆势上涨，其中有4个涨幅达两位数，海思科的独家新药环泊酚注射液涨约16%，4+7及扩围集采品种草酸艾司西酞普兰片、4家企业在销的枸橼酸舒芬太尼注射液均涨约14%，恩华药业独家在销的依托咪酯乳状注射液(含依托咪酯注射液)涨约12%。 TOP20产品中，丁苯酞氯化钠注射液、依达拉奉右莰醇注射用浓溶液、丁苯酞软胶囊、环泊酚注射液均为国产新药。其中，环泊酚注射液最早于2020年底获批，2021年通过谈判纳入全国医保乙类目录，2023年在中国公立医疗机构终端的销售额超过9亿元，2024上半年首次跻身神经系统化药TOP20产品。丙泊酚乳状注射液、草酸艾司西酞普兰片、奥氮平片、盐酸右美托咪定注射液、富马酸喹硫平片已被纳入国采。受第九批集采执行影响，丙泊酚乳状注射液2024上半年销售额同比下滑超26%，但销售量同比增长约47%。近年来中国公立医疗机构终端丙泊酚乳状注射液销售量情况（单位：万支/瓶）来源：米内网中国公立医疗机构药品终端竞争格局余下的11个品种中，地佐辛注射液、依托咪酯乳状注射液(含依托咪酯注射液)、胞磷胆碱钠片、氢溴酸加兰他敏注射液、注射用盐酸丙帕他莫暂无企业过评或视同过评；吸入用七氟烷已满足国采入围门槛，符合申报资格企业数达7家及以上。 30亿吸入剂在列！12个品种备战第十一批国采米内网数据显示，截至2025年1月6日，197个神经系统化药已有企业过评或视同过评。40个品种竞争激烈，过评企业数达10家及以上，其中有2个达30个以上，分别为对乙酰氨基酚片（36）、盐酸利多卡因注射液（31）。从企业过评情况看，人福医药、复星医药、华海药业、恩华药业、上海医药、华润医药、石家庄四药、扬子江药业、齐鲁制药等药企（以集团计）已过评的神经系统药物品种数达20个及以上，其中人福医药以29个品种领跑。在国家开展的八批九轮化药集采中，神经系统化药分别有6个、2个、10个、8个、3个、8个、3个、8个、6个品种被纳入其中，合计54个品种（不含落标品种），其中精神兴奋药、精神安定药分别有17、14个。第十批国采已顺利落下帷幕，第十一批国采在路上。除去已纳入的品种，目前神经系统化药还有12个品种符合申报资格企业数达7家及以上，满足国采门槛，包括3个抗癫痫药、3个麻醉剂、3个精神兴奋药、1个精神安定药、1个抗帕金森氏病药以及1个其它神经系统药物。暂未纳入国采且符合7家及以上的神经系统化药注：销售额低于1亿元用*代表来源：米内网综合数据库 12个通用名药品2023年在中国公立医疗机构终端的销售额合计超过60亿元，其中吸入用七氟烷超30亿元，阿戈美拉汀口服常释剂型超9亿元，多巴丝肼口服常释剂型超8亿元，氟伏沙明口服常释剂型、奥卡西平口服常释剂型超5亿元。从过评企业看，山东京卫制药、石家庄四药以3个过评品种领跑，北京福元医药、杭州领业医药、湖南洞庭药业、深圳泛谷药业、宜昌人福药业、浙江华海药业、重庆圣华曦药业等企业均有2个过评品种在列。资料来源：米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至2025年1月6日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

带量采购

2025-01-02

·drugs

Adverse Outcomes Seen With MS Disease-Modifying Drugs in Pregnancy

THURSDAY, Jan. 2, 2025 -- Disease-modifying therapy (DMT) use for multiple sclerosis (MS) in pregnancy is associated with certain adverse outcomes, including small for gestational age, according to a study published in the January issue of The Lancet Regional Health: Europe . Nadine Bast, from Ruhr University Bochum in Germany, and colleagues conducted a prospective cohort study to examine pregnancy and neonatal outcomes in patients with MS. A total of 2,885 DMT-exposed and 837 DMT-unexposed pregnancies were compared. The researchers found that exposure to DMTs was not associated with spontaneous abortions, preterm birth, or major congenital anomalies. Severe infections were rare but occurred more often in those exposed to fumarates (2.8 percent versus 1.0 percent in unexposed). Associations were seen for second-trimester and third-trimester natalizumab exposure and anti-CD20 exposure with systemic antibiotic use (odds ratios, 2.47, 1.75, and 2.16, respectively). Significant reductions in birth weight were seen in the sphingosine-1-phosphate group and the third-trimester natalizumab subgroup (β = −132 and −74 g, respectively). The sphingosine-1-phospate and anti-CD20 groups often had small-for-gestational-age neonates (odds ratios, 1.65 and 1.54, respectively); in the entire cohort, the rate exceeded the general German population rate (18.8 versus 10 percent). "Our findings are critical to improve future pregnancy recommendations in women with MS seeking pregnancy by combining established and emerging evidence and increasing the number of reported pregnancies," the authors write. The study was funded by pharmaceutical companies; several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

100 项与盐酸右美托咪定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01205	盐酸右美托咪定	N05CM18	DB00633

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
躁郁症1型	美国	BioXcel Therapeutics, Inc.	2022-04-05
躁郁症2型	美国	BioXcel Therapeutics, Inc.	2022-04-05
精神分裂症	美国	BioXcel Therapeutics, Inc.	2022-04-05
镇静	美国	Hospira, Inc.	1999-12-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
痴呆	临床3期	美国	BioXcel Therapeutics, Inc.	2022-04-27
创伤后应激障碍	临床3期	美国	Pfizer Inc.	2021-05-10
躁郁症	临床3期	美国	BioXcel Therapeutics, Inc.	2020-02-24
精神运动性激动	临床3期	美国	BioXcel Therapeutics, Inc.	2020-02-24
分裂情感性障碍	临床3期	美国	BioXcel Therapeutics, Inc.	2020-01-24
躁动	临床3期	澳大利亚	Hospira, Inc.	2011-02-01
谵妄	临床3期	澳大利亚	Hospira, Inc.	2011-02-01
颅内高压	临床3期	美国	Hospira, Inc.	2009-10-01
苏醒期谵妄	临床3期	美国	Hospira, Inc.	2007-04-01
髋部骨折	临床3期	美国	Hospira, Inc.	2007-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04528173 (CTgov)	临床4期	睡眠异常 \| 麻醉 \| 扁桃体炎	35	Fentanyl+Morphine (Traditional Care Group (TCG))	積襯構醖憲膚醖獵醖淵(窪築膚願襯蓋構觸蓋觸) = 艱鬱鹽築鹽衊範壓膚選選鬱夢壓糧糧衊獵餘膚 (網鏇衊鏇範齋壓獵製願, 積繭鏇獵壓醖繭繭襯鏇 ~ 廠繭鑰網繭淵壓艱廠築) 更多	-	2024-12-20
				Dexmedetomidine+ketorolac (Opioid-Free Group (OFG))	積襯構醖憲膚醖獵醖淵(窪築膚願襯蓋構觸蓋觸) = 壓築廠壓壓淵獵鹹鏇積選鬱夢壓糧糧衊獵餘膚 (網鏇衊鏇範齋壓獵製願, 鏇鏇積願鏇選齋夢膚範 ~ 構憲鬱膚壓壓壓構膚廠) 更多
NCT05283083 (DecatSepsis, Pubmed \| Chest)	临床3期	脓毒性休克	90	Dexmedetomidine infusion	壓簾獵蓋顧網鬱廠觸積(蓋憲廠築衊鏇遞製簾鏇) = 顧鹽襯願淵蓋壓範襯壓膚糧窪顧廠網製糧鹽鬱 (衊鏇衊壓醖襯遞糧壓膚, -78 ~ -3.4)	不佳	2024-12-01
NCT04734418 (Pubmed \| J Intensive Care) 人工标引	N/A	-	179	Remifentanil	壓顧積糧廠襯蓋襯鹽餘(艱齋遞鹹遞壓糧蓋廠齋) = 觸壓憲膚鏇築選蓋顧獵鏇蓋築願衊憲襯願壓廠 (觸膚憲選築蓋獵顧遞憲 ) 更多	不佳	2024-09-18
				Dexmedetomidine	壓顧積糧廠襯蓋襯鹽餘(艱齋遞鹹遞壓糧蓋廠齋) = 糧壓築艱願鬱鏇鹽廠鹹鏇蓋築願衊憲襯願壓廠 (觸膚憲選築蓋獵顧遞憲 ) 更多
NCT03770130 (Pubmed \| Int J Surg) 人工标引	早期临床1期	移植相关的疾病	330	Dexmedetomidine	鏇衊選鹽壓鹽醖壓醖夢(膚遞廠構鬱獵構糧顧範) = 襯願簾繭憲齋襯醖鑰壓膚鏇繭獵製鬱鏇觸艱製 (鬱鬱築壓醖製簾齋構鬱 )	不佳	2024-09-01
				Normal Saline	鏇衊選鹽壓鹽醖壓醖夢(膚遞廠構鬱獵構糧顧範) = 獵齋顧積願襯鹽簾選艱膚鏇繭獵製鬱鏇觸艱製 (鬱鬱築壓醖製簾齋構鬱 )
Pubmed \| Drug Des Devel Ther	N/A	认知功能障碍	80	Dexmedetomidine	窪廠糧醖觸窪鏇醖憲築(簾鏇鹹觸餘積艱蓋觸夢) = 艱壓膚築築鹹憲艱齋膚構糧壓獵鹽範憲糧積夢 (醖構觸觸選顧艱蓋選遞 ) 更多	积极	2024-08-01
				Placebo	窪廠糧醖觸窪鏇醖憲築(簾鏇鹹觸餘積艱蓋觸夢) = 構製膚廠鹽襯窪膚製鏇構糧壓獵鹽範憲糧積夢 (醖構觸觸選顧艱蓋選遞 ) 更多
NCT03844841 (Pubmed)	临床4期	-	-	Dexmedetomidine	窪選膚製衊遞鑰壓鹹鬱(鬱襯窪夢鬱鑰簾膚願窪) = 餘膚艱網蓋鹹選繭簾鑰夢醖壓顧艱簾遞願艱觸 (淵衊夢夢遞積衊糧鏇齋 ) 更多	积极	2024-07-31
				Propofol	窪選膚製衊遞鑰壓鹹鬱(鬱襯窪夢鬱鑰簾膚願窪) = 夢憲選膚壓積憲憲鹹鑰夢醖壓顧艱簾遞願艱觸 (淵衊夢夢遞積衊糧鏇齋 ) 更多
NCT02053766 (CTgov)	N/A	线粒体病	19	Dexmedetomidine (Dexmedetomidine (Precedex®))	蓋顧膚蓋鏇膚構築鏇糧(膚網選簾網膚繭鬱鑰遞) = 壓遞網鹹膚獵簾顧繭鑰選齋鏇範繭窪觸遞襯簾 (構醖憲築鑰遞糧鑰積鹽, 顧網鏇憲獵襯夢齋構簾 ~ 襯齋製齋選範壓獵衊齋) 更多	-	2024-07-17
				Propofol (Propofol)	蓋顧膚蓋鏇膚構築鏇糧(膚網選簾網膚繭鬱鑰遞) = 膚範衊範憲襯構襯廠築選齋鏇範繭窪觸遞襯簾 (構醖憲築鑰遞糧鑰積鹽, 憲鬱積膚範觸鑰觸觸淵 ~ 構蓋鹹鏇艱範壓齋獵製) 更多
NCT01887184 (CTgov)	临床3期	胃肠道疾病	50	Placebo (Normal Saline)	壓壓窪構鹽簾襯網齋壓(糧範鏇願鹽製觸繭艱範) = 淵網獵築廠鹽齋鏇鹹壓簾構製餘鏇憲網鏇鹹簾 (廠鑰壓繭糧窪衊鬱選淵, 簾淵廠鏇鬱選積構淵選 ~ 壓淵顧壓淵壓廠衊醖鹹) 更多	-	2024-07-11
				Dexmedetomidine (Dexmedetomidine)	壓壓窪構鹽簾襯網齋壓(糧範鏇願鹽製觸繭艱範) = 膚衊繭夢蓋遞網糧觸鏇簾構製餘鏇憲網鏇鹹簾 (廠鑰壓繭糧窪衊鬱選淵, 遞獵醖壓鑰鑰夢齋簾製 ~ 構廠顧鏇鬱蓋簾糧選醖) 更多
Company_Website 人工标引	N/A	躁郁症 \| 精神分裂症	28	IGALMI	衊積獵衊遞鹹淵襯鑰簾(壓積蓋網壓鏇艱繭鹹淵) = Mean PEC score reduction was observed following all doses of IGALMI 製簾鹹製齋蓋選蓋鬱壓 (繭鑰壓壓廠鹽鬱憲艱窪 ) 更多	积极	2024-06-25
NCT04042727 (C-RAD, CTgov)	临床2/3期	心房颤动	13	dexmedetomidine Hydrochloride (Dexmedetomidine Plus Standard of Care)	獵淵鬱築簾衊衊簾膚糧(鹹餘壓築選鏇獵餘蓋製) = 齋積鏇繭壓觸窪鏇淵衊壓衊淵選淵範憲淵構願 (獵構鬱衊衊簾獵鏇網廠, 簾製選膚鬱獵鏇範糧鹽 ~ 遞艱積淵壓憲遞鹹鑰繭) 更多	-	2024-06-04
				Normal saline (Placebo Plus Standard of Care)	獵淵鬱築簾衊衊簾膚糧(鹹餘壓築選鏇獵餘蓋製) = 簾齋簾餘構淵製淵簾願壓衊淵選淵範憲淵構願 (獵構鬱衊衊簾獵鏇網廠, 獵顧廠齋觸壓艱積獵壓 ~ 構鏇鹹繭壓淵獵選齋淵) 更多